Navigation Links
DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
Date:5/2/2013

ator Zogenix reporting positive results from the Relday Phase 1 study and rapid expansion of that study to include a higher dose, which today also reported positive results."

Update of Programs:

  • REMOXY (oxycodone) Extended-Release Capsules CII.  Pfizer has efforts underway to resolve the issues raised in the REMOXY Complete Response Letter, which are primarily related to manufacturing. Pfizer held a meeting with the FDA in late March 2013 to discuss their proposed resubmission plan for REMOXY.  On April 30, Pfizer stated that they had a productive meeting with the FDA and received guidance that is helping to inform the next steps in addressing the issues raised by the FDA in the Complete Response Letter.  In 2013, we received issuance of an additional ORADUR® patent that would protect REMOXY in the U.S. until at least 2031. 
    On April 16, 2013, the FDA announced two actions relevant to abuse-deterrent opioids.  First, after reviewing the available science, the FDA will allow the label for opioids to describe abuse-deterrent properties.  Second, the FDA will not accept or approve any generic forms of the original OxyContin ER.
    REMOXY, an investigational drug, is a unique long acting oral formulation of oxycodone intended to treat moderate-to-severe pain when a continuous, around the clock opioid analgesic is needed for an extended period of time. Based on DURECT's ORADUR technology, which is covered by issued patents and pending patent applications owned by us, REMOXY is designed to discourage common methods of tampering associated with prescription opioid analgesic misuse and abuse.
  • POSIDUR (SABER®-Bupivacaine) Post-Operative Pain Relief Depot. In April 2013, we submitted a new drug application (NDA) as a 505(b)(2) application, which relies in part on the FDA's findings of safety and effectiveness of a reference drug.  We expect that the FDA will n
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
    2. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
    3. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
    4. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
    5. DURECT to Participate in Upcoming Healthcare Conferences
    6. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
    7. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
    8. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
    9. Luminex Corporation Reports First Quarter 2013 Results
    10. Comprehensive Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
    11. Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... 22, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... announce that TUV-SUD and The Medicinal Evaluation Board ... has granted its request for a label expansion ... initially approved in July 2013 for use in ...
    (Date:9/22/2014)... PLEASANTON, Calif. , Sept. 22, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... D. Keith Grossman has been appointed President and ... F. Burbach , who has stepped down from his ... advisor to the company through the first quarter of ...
    (Date:9/22/2014)... Sept. 22, 2014 Auxilium Pharmaceuticals, Inc. ... company, today announced that its Board of Directors ... conditional proposal from Endo International plc ("Endo") and, ... advisors, has unanimously determined it is not a ... merger agreement with QLT Inc. ("QLT") and has ...
    Breaking Medicine Technology:Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
    ... Based on its recent analysis of the ... Hybridyne Technologies, Inc. with the 2010 North American ... the Year. (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ... ProxiScan™, recently approved by the FDA, is ...
    ... Upstate New York Laboratory Robotics Interest Group (LRIG) ... Society of Mechanical Engineers (ASME) will be hosting ... 27, 2010 entitled "Unconventional High-Throughput Applications," featuring Pankaj ... Seth Cohen, Ph.D., Senior Director Microfluidics Applications, Caliper ...
    Cached Medicine Technology:Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 2Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 3Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 4Upstate New York Laboratory Robotics Interest Group (LRIG) to Host Free Symposium and Exhibition 2
    (Date:9/22/2014)... New York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , ... for hip bursitis treatment in Manhattan. This treatment is now offered ... bursitis, which is also called trochanteric bursitis, occurs when ... is a fluid-filled sac in the hip, between the ...
    (Date:9/22/2014)... eye transplant seems futuristic, if not impossible. But ... of Defense, researchers at University of California, San ... implantation of an entire, functional eye a reality. ... holy grail for vision restoration," said Jeffrey Goldberg, ... with colleagues at University of Pittsburg Medical Center ...
    (Date:9/22/2014)... 22, 2014 This Flash Report is ... management needs for the Prostate Cancer market. , Download ... stakeholder strategies for any launching Prostate Cancer product:, ... within an increasingly crowded market , Understanding ... of identifying community-based thought leaders and stakeholders ,Download ...
    (Date:9/22/2014)... The Workgroup for Electronic ... authority on the use of health IT to ... from its recent industry survey on the use ... electronic transactions adopted under the Health Insurance Portability ... from August 20 to September 5, which included ...
    (Date:9/22/2014)... CareFlight Air & Mobile Services of ... AS365 N3+ Dauphin, the latest version of Airbus Helicopters ... based at Miami Valley Hospital in Dayton, ... transport helicopters. , “We have a lot of confidence ... President, Emergency, Trauma, and CareFlight. “We’ve been operating Dauphins ...
    Breaking Medicine News(10 mins):Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
    ... released new clinical guidelines for the treatment of exacerbations ... literature on current clinical practices. "This is the ... practices for pulmonary exacerbation of cystic fibrosis," said Susanna ... and director of the Cystic Fibrosis Center at Children,s ...
    ... N.C. Studies by researchers at Wake Forest University ... receptor in immature rats leads to profound, rapid brain ... mature. The N-methyl-D-aspartate (NMDA) receptor is activated ... released by brain cells. This allows calcium to enter ...
    ... at-risk American adults who would benefit from vaccination against seasonal ... believe they do not need them and are not inclined ... intend to take up the vaccine, nearly half get around ... Corporation* in Arlington, USA, and her team. Their work (1) ...
    ... prescriptions issued by GPs has been caused by a year ... drugs on a long-term basis, according to researchers from the ... printed edition of British Medical Journal ( BMJ ... number of new patients diagnosed with depression over 11 years, ...
    ... chance of success , THURSDAY, Oct. 22 (HealthDay News) -- ... offer the best chance of success with in vitro fertilization ... selecting embryos for implantation in the mother,s womb is highly ... IVF failure or multiple pregnancies," Dr. Emre Seli, an associate ...
    ... medication leads to better outcome, researchers say , ... say they have a better treatment for patients ... standard therapy. , Their study finds that treatment ... better short-term survival and with lower toxicity than ...
    Cached Medicine News:Health News:New clinical guidelines for exacerbations in cystic fibrosis 2Health News:General anesthetics lead to learning disabilities in animal models 2Health News:General anesthetics lead to learning disabilities in animal models 3Health News:Flu shots not to be sneezed at 2Health News:Assessing Embryo Metabolism May Aid IVF Success 2Health News:Study Finds Less Toxic Treatment for Myeloma 2
    Palm Style Impactor Bone Awl with Ortho-Grip® silicone rubber handles and,stainless steel impactor caps....
    CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi...
    The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
    Steroid eluting pacemaker leads...
    Medicine Products: